- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05054985
Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.
January 15, 2024 updated by: Lifetech Scientific (Shenzhen) Co., Ltd.
Guo's Renovisceral Artery Reconstruction-1: a Prospective, Multicenter, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of a Multi-branched Stent Graft System for Thoracoabdominal Aortic Aneurysm (GUARANTEE Study)
Evaluation of the safety and efficacy of a multi-branched thoracoabdominal stent graft system for thoracoabdominal aortic aneurysm.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is mainly for patients with thoracoabdominal aortic aneurysms, and all subjects who signed the informed consent and passed the screening will be enrolled.
Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system.
Patients will be followed up at discharge, 1 month, 6 months, 12 months after the implantation.
Study Type
Interventional
Enrollment (Estimated)
73
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wei Guo, Professor
- Phone Number: 86 13910758706
- Email: pla301dml@vip.sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Chinese PLA General Hospital
-
Contact:
- Wei Guo
-
Principal Investigator:
- Wei Guo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 years old ≤ age ≤ 80 years old;
Diagnosed as thoracoabdominal aortic aneurysm (based on modified Crawford classification and 2019 European Guidelines for the Treatment of Aortic aneurysm) and should meet at least one of the following conditions;
- Maximum diameter of thoracoabdominal aortic aneurysm>50mm;
- The diameter has increased by more than 5mm in recent 6 months or the by more than 10mm in recent 1 year;
anatomical criteria
- The proximal anchoring region (aorta or implanted graft) was 17~36 mm in diameter and ≥25 mm in length;
- Distal anchoring region (aorta or implanted graft): If the distal anchoring region is in the iliac artery, the anchoring region has a diameter range of 7~25 mm and a length of ≥15 mm; If the distal anchoring area is in the abdominal aorta, the diameter of the anchoring area ranges from 12~36mm and the length≥ 20mm;
- The diameter of the vessel anchoring area of the visceral branch ranges from 6~13 mm and the length ≥15 mm;
- The diameter of renal artery anchoring area ranges from 4.5~9mm, and the length ≥15 mm;
- Appropriate iliac, femoral and upper limb artery access;
- Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol;
Exclusion Criteria:
- Hemodynamically unstable patients with ruptured thoracoabdominal aortic aneurysms;
- Thoracoabdominal aortic dissection;
- Mycotic or infectious thoracoabdominal aortic aneurysm;
- Patients whose systemic or local infection may increase the risk of intravascular graft infection;
- Superior mesenteric, celiac, or renal artery occlusion;
- Requiring simultaneous coverage and embolization of bilateral internal iliac arteries;
- Severe stenosis, calcification, or mural thrombus in the anchoring area of the stent tend to have difficulty in attachment of the stent-graft or affect the patency of the stent;
- A history of acute coronary syndrome within 6 months; Acute coronary syndrome is defined as an acute ischemic syndrome of the heart resulting from the rupture or erosion of unstable intracoronary atherosclerotic plaques followed by fresh thrombosis, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina pectoris.
- Transient ischemic attack (TIA) or ischemic/haemorrhagic stroke within 3 months;
- Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol/L;
- Severe pulmonary insufficiency who cannot tolerate general anaesthesia;
- Severe coagulation dysfunction;
- Undergone major surgical or interventionic surgery within 30 days before surgery;
- A history of allergy to contrast agents, anticoagulants, antiplatelet drugs, stents, and conveyor materials (nitinol, polyester, PTFE, nylon);
- Connective tissue diseases such as systemic lupus erythematosus, Marfan's syndrome, Adam's syndrome, or Behcet's disease;
- takayasu arteritis;
- Serious vital organ dysfunction or other serious disease;
- Planning pregnancy, pregnancy, or breastfeeding;
- Patients who participated in other clinical trials and was not discontinued or withdrawn within the first 3 months of the screening period of this trial.
- Life expectancy less than 1 year;
- Patients who, in the judgment of the investigator, are not eligible for endotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Patients with thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
|
Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary safety endpoint: The incidence of Major Adverse events (MAE) within 30 days after procedure.
Time Frame: Within 30 days after procedure
|
Major Adverse Event (MAE) was defined as all-cause death, liver failure, intestinal necrosis, kidney failure, stroke, permanent paraplegia, myocardial infarction, and respiratory failure.
|
Within 30 days after procedure
|
Primary efficacy endpoint: Success rate of thoracoabdominal aortic aneurysm treatment 12 months after procedure.
Time Frame: 12 months after procedure.
|
Successful treatment of thoracoabdominal aortic aneurysm is a composite index that needs to meet the following indicators at the same time: Immediate technical success (immediate technical success refers to the successful delivery system to a predetermined location, the successful deployment of the system and the safe withdrawal of the delivery system from the body and no type I/III endoleak), no secondary surgical intervention related to thoracoabdominal aortic aneurysms 12 months after procedure (due to aneurysm rupture, continuous enlargement, stent displacement, type I/III endoleak, branch stenosis/ Second surgery caused by occlusion) .
|
12 months after procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
aneurysmal enlargement at 6 and 12 months postoperatively
Time Frame: 6 and 12 months postoperatively
|
aneurysmal enlargement defined as a maximum aortic diameter increase of > 5 mm relative to preoperative computed tomography angiography (CTA)
|
6 and 12 months postoperatively
|
type I/III endoleak at 6 and 12 months postoperatively
Time Frame: 6 and 12 months postoperatively
|
6 and 12 months postoperatively
|
|
stent graft migration at 6 and 12 months postoperatively
Time Frame: 6 and 12 months postoperatively
|
6 and 12 months postoperatively
|
|
renovisceral artery patency rate at 6 and 12 months postoperatively
Time Frame: 6 and 12 months postoperatively
|
6 and 12 months postoperatively
|
|
reintervention secondary to TAAA progression at 6 months, 12 months, and 2-5 years postoperatively.
Time Frame: 6 months, 12 months, and 2-5 years postoperatively.
|
6 months, 12 months, and 2-5 years postoperatively.
|
|
delivery system-related complications during the procedure and within 30 days postoperatively, including conversion to open surgery, and any hemorrhage, hematoma, or pseudoaneurysm of the arterial access
Time Frame: during the procedure and within 30 days postoperatively
|
during the procedure and within 30 days postoperatively
|
|
all-cause mortality at 6 months, 12 months, and 2-5 years postoperatively
Time Frame: 6 months, 12 months, and 2-5 years postoperatively
|
6 months, 12 months, and 2-5 years postoperatively
|
|
TAAA-related mortality at 6 months, 12 months, and 2-5 years postoperatively
Time Frame: 6 months, 12 months, and 2-5 years postoperatively
|
6 months, 12 months, and 2-5 years postoperatively
|
|
device-related adverse events at 6 months, 12 months, and 2-5 years postoperatively
Time Frame: 6 months, 12 months, and 2-5 years postoperatively
|
6 months, 12 months, and 2-5 years postoperatively
|
|
severe adverse events resulting in death or serious deterioration of health at 6 months, 12 months, and 2-5 years postoperatively
Time Frame: 6 months, 12 months, and 2-5 years postoperatively
|
6 months, 12 months, and 2-5 years postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Wei Guo, Professor, Chinese PLA General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 12, 2021
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
September 7, 2021
First Submitted That Met QC Criteria
September 14, 2021
First Posted (Actual)
September 23, 2021
Study Record Updates
Last Update Posted (Estimated)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 15, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XJ-TAAA-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data will be shared for scientific purposes after the completion of the clinical trial.
However, patients' electronic records and any CTA files are outside the scope of our data sharing policy.
Researchers wanting to request data can submit a detailed application to the investigators.
Data will be released depending on the scientific quality of the submitted request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracoabdominal Aortic Aneurysms
-
Gustavo OderichCook Group IncorporatedRecruitingJuxtarenal Aortic Aneurysms | Suprarenal Aortic Aneurysms | Type IV Thoracoabdominal Aortic AneurysmsUnited States
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
IRCCS San RaffaeleCompletedThoracoabdominal Aneurysms and Para-renal Aortic AneurysmsItaly
-
Lifetech Scientific (Shenzhen) Co., Ltd.Unknown
-
Scientific Institute San RaffaeleCompleted
-
Sanford HealthActive, not recruitingThoracoabdominal AneurysmsUnited States
-
IRCCS San RaffaeleCompletedThoracoabdominal Aortic AneurysmsItaly
-
IRCCS San RaffaeleCompletedAortic Aneurysm, Thoracoabdominal | Para-renal Aortic AneurysmsItaly
-
The Christ HospitalMedtronicRecruiting
Clinical Trials on Multi-Branched Thoracoabdominal Stent Graft System
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Xijing HospitalUnknown
-
Matthew EagletonMedtronic; NAMSA; Sanford HealthActive, not recruitingThoracoabdominal Aortic AneurysmUnited States
-
The Christ HospitalMedtronicRecruiting
-
Liang-Wan Chen MDRenJi Hospital; Xinqiao Hospital of Chongqing; Longyan City First Hospital; First... and other collaboratorsUnknown
-
Timothy Chuter, MDRecruitingThoracoabdominal Aortic Aneurysm | Paravisceral Abdominal Aortic AneurysmUnited States
-
China National Center for Cardiovascular DiseasesActive, not recruitingAortic Dissection | Aortic Intramural Hematoma | Aneurysm, Aortic Arch | Aortic Pseudoaneurysm | Aortic Ulcer, PenetratingChina
-
Fujian Medical UniversityCompletedAcute Aortic DissectionChina
-
University Paul Sabatier of ToulouseCompleted